Hydrogen
- Generic Name
- Hydrogen
- Drug Type
- Small Molecule
- Chemical Formula
- H2
- CAS Number
- 1333-74-0
- Unique Ingredient Identifier
- 7YNJ3PO35Z
- Background
Hydrogen is under investigation in clinical trial NCT02830854 (Molecular Hydrogen for Cognitive Function and Performance in Elderly).
FDA Grants Orphan Drug Designation to DiagnaMed's Molecular Hydrogen Therapy for ALS
• DiagnaMed Holdings Corp. has received FDA Orphan Drug Designation for molecular hydrogen as a potential treatment for ALS, offering key development incentives including seven years of market exclusivity.
• The company has entered into a letter of intent with Revive Therapeutics Ltd. to transfer full rights of its molecular hydrogen intellectual property for ALS treatment, with the acquisition expected to close by March 31, 2025.
• Molecular hydrogen's antioxidant and anti-inflammatory properties show promise in addressing oxidative stress and inflammation in ALS, a devastating neurodegenerative disease affecting 50,000 patients in the U.S. and Europe.
Revive Therapeutics to Acquire DiagnaMed's Molecular Hydrogen Program for ALS and Brain Disorders
• Revive Therapeutics has signed a letter of intent to acquire DiagnaMed's molecular hydrogen intellectual property portfolio, including an FDA Orphan Drug Designation for ALS treatment.
• The acquisition includes patent applications for novel pharmaceutical-grade hydrogen-producing compositions targeting various neurological conditions including Dementia, Parkinson's disease, and mental health disorders.
• The deal aims to accelerate development of molecular hydrogen therapy for ALS, which affects 50,000 patients in the US and Europe, with potential closing expected by March 31, 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath